The ADAMs family of proteases as targets for the treatment of cancer

Cancer Biology and Therapy

Volumn 17, Issue 8, 2016, Pages 870-880

  Mullooly, Maeve ^a,b   McGowan, Patricia M ^b,c   Crown, John ^c   Duffy, Michael J ^b,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

ADAM10; ADAM17; ADAMs; cancer; inhibitors; therapy

Indexed keywords

A DISINTEGRIN AND METALLOPROTEASE 12 PROTEIN; A DISINTEGRIN AND METALLOPROTEASE 15 PROTEIN; A DISINTEGRIN AND METALLOPROTEASE 17 PROTEIN; A DISINTEGRIN AND METALLOPROTEASE 22 PROTEIN; A DISINTEGRIN AND METALLOPROTEASE 28 PROTEIN; A DISINTEGRIN AND METALLOPROTEASE 8 PROTEIN; A DISINTEGRIN AND METALLOPROTEASE 9 PROTEIN; A DISINTEGRIN AND METALLOPROTEASE PROTEIN INHIBITOR; ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; ADERBASIB; ANTINEOPLASTIC AGENT; BK 1361; METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; N [2,2 DIMETHYL 1 [(METHYLAMINO)CARBONYL]PROPYL] 2 [1 [FORMYL(HYDROXY)AMINO]ETHYL] 5 PHENYLPENTAMIDE; PF 5480090; TRASTUZUMAB; UNCLASSIFIED DRUG; [METHY 7 (HYDROXYCARBAMOYL) 6 ( 4 PHENYL 3,6 DIHYDRO 2H PYRIDINE 1 CARRBONYL) 5 AZASPIRO[2.5]OCTANE 5 CARBOXYLATE];

CANCER GROWTH; CARCINOGENESIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR PATHOLOGY; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; ANIMAL; CELL PROLIFERATION; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

ADAM PROTEINS; ANIMALS; CELL PROLIFERATION; HUMANS; NEOPLASMS;

EID: 84979984706     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1177684     Document Type: Review

References (104)

1. D.Hanahan, R.A.Weinberg. Hallmarks of cancer:the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
2. B.Vogelstein, N.Papadopoulos, V.E.Velculescu, S.Zhou, L.A.DiazJr, K.W.Kinzler. Cancer genome landscapes. Science 2013; 339:1546-58; PMID:23539594; http://dx.doi.org/10.1126/science.1235122
3. S.Weber, P.Saftig. Ectodomain shedding and ADAMs in development. Development 2012; 139:3693-709; PMID:22991436; http://dx.doi.org/10.1242/dev.076398
4. M.J.Duffy, E.McKiernan, N.O'Donovan, P.M.McGowan. The role of ADAMs in disease pathophysiology. Clin Chim Acta 2009; 403:31-6; PMID:19408347; http://dx.doi.org/10.1016/j.cca.2009.01.007
5. M.J.Duffy, E.McKiernan, N.O'Donovan, P.M.McGowan. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009; 15:1140-4; PMID:19228719; http://dx.doi.org/10.1158/1078-0432.CCR-08-1585
6. D.Singh, S.K.Srivastava, T.K.Chaudhuri, G.Upadhyay. Multifaceted role of matrix metalloproteinases (MMPs). Front Mol Biosci 2015; 2:19; PMID:25988186; http://dx.doi.org/10.3389/fmolb.2015.00019
7. J.C.Jones, S.Rustagi, P.J.Dempsey. ADAM Proteases and gastrointestinal function. Annu Rev Physiol. 2016 Feb 10;78:243-76; PMID:26667078; http://dx.doi.org/10.1146/annurev-physiol-021014-071720
8. J.D.Leonard, F.Lin, M.E.Milla. Chaperone-like properties of the prodomain of TNFalpha-converting enzyme (TACE) and the functional role of its cysteine switch. Biochem J 2005; 387:797-805; PMID:15581423; http://dx.doi.org/10.1042/BJ20041727
9. P.Reddy, J.L.Slack, R.Davis, D.P.Cerretti, C.J.Kozlosky, R.A.Blanton, D.Shows, J.J.Peschon, R.A.Black. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 2000; 275:14608-14; PMID:10799547; http://dx.doi.org/10.1074/jbc.275.19.14608
10. K.Reiss, A.Ludwig, P.Saftig. Breaking up the tie:disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol Ther 2006; 111:985-1006; PMID:16626807; http://dx.doi.org/10.1016/j.pharmthera.2006.02.009
11. A.R.Haltom, H.Jafar-Nejad. The multiple roles of epidermal growth factor repeat O-glycans in animal development. Glycobiol 2015; 25:1027-42; PMID:26175457; http://dx.doi.org/10.1093/glycob/cwv052
12. T.Maretzky, A.Evers, S.Le Gall, R.O.Alabi, N.Speck, K.Reiss, C.P.Blobel. The cytoplasmic domain of a disintegrin and metalloproteinase 10 (ADAM10) regulates its constitutive activity but is dispensable for stimulated ADAM10-dependent shedding. J Biol Chem 2015; 290:7416-25; PMID:25605720; http://dx.doi.org/10.1074/jbc.M114.603753
13. E.Díaz-Rodríguez, J.C.Montero, A.Esparís-Ogando, L.Yuste, A.Pandiella. Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735:a potential role in regulated shedding. Mol Biol Cell 2002; 13:2031-44; PMID:12058067; http://dx.doi.org/10.1091/mbc.01-11-0561
14. S.Düsterhöft, K.Höbel, M.Oldefest, J.Lokau, G.H.Waetzig, A.Chalaris, C.Garbers, J.Scheller, S.Rose-John, I.Lorenzen, J.Grötzinger. A disintegrin and metalloprotease 17 dynamic interaction sequence, the sweet tooth for the human interleukin 6 receptor. J Biol Chem 2014; 289:16336-48; PMID:24790088; http://dx.doi.org/10.1074/jbc.M114.557322
15. I.Lorenzen, J.Lokau, S.Düsterhöft, A.Trad, C.Garbers, J.Scheller, S.Rose-John, J.Grötzinger. The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett 2012; 586:1093-100; PMID:22575642; http://dx.doi.org/10.1016/j.febslet.2012.03.012
16. S.Düsterhöft, M.Michalek, F.Kordowski, M.Oldefest, A.Sommer, J.Röseler, K.Reiss, J.Grötzinger, I.Lorenzen. Extracellular juxtamembrane segment of ADAM17 Interacts with membranes and is essential for its shedding activity. Biochemistry 2015; 54:5791-801; PMID:26348730; http://dx.doi.org/10.1021/acs.biochem.5b00497
17. T.Tousseyn, A.Thathiah, E.Jorissen, T.Raemaekers, U.Konietzko, K.Reiss, E.Maes, A.Snellinx, L.Serneels, O.Nyabi, W.Annaert, P.Saftig, D.Hartmann, B.De Strooper. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. J Biol Chem 2009; 284:11738-47; PMID:19213735; http://dx.doi.org/10.1074/jbc.M805894200
18. R.A.Black, C.T.Rauch, C.J.Kozlosky, J.J.Peschon, J.L.Slack, M.F.Wolfson, B.J.Castner, K.L.Stocking, P.Reddy, S.Srinivasan, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385:729-33; PMID:9034190; http://dx.doi.org/10.1038/385729a0
19. M.L.Moss, S.L.Jin, J.D.Becherer, D.M.Bickett, W.Burkhart, W.J.Chen, D.Hassler, M.T.Leesnitzer, G.McGeehan, M.Milla, et al. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol 1997; 72:127-9; PMID:9042103; http://dx.doi.org/10.1016/S0165-5728(96)00180-4
20. M.Kveiborg, R.Instrell, C.Rowlands, M.Howell, P.J.Parker. PKCα and PKCδ regulate ADAM17-mediated ectodomain shedding of heparin binding-EGF through separate pathways. PLoS One 2011; 6:e17168; PMID:21386996; http://dx.doi.org/10.1371/journal.pone.0017168
21. M.Dang, K.Dubbin, A.D'Aiello, M.Hartmann, H.Lodish, A.Herrlich. Epidermal growth factor (EGF) ligand release by substrate-specific a disintegrin and metalloproteases (ADAMs) involves different protein kinase C (PKC) isoenzymes depending on the stimulus. Dang M1, Dubbin K, D'Aiello A, Hartmann M, Lodish H, Herrlich A. J Biol Chem 2011; 286:17704-13; PMID:21454702; http://dx.doi.org/10.1074/jbc.M110.187823
22. P.Xu, R.Derynck. Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Mol Cell 2010; 37:551-66; PMID:20188673; http://dx.doi.org/10.1016/j.molcel.2010.01.034
23. P.Xu, J.Liu, M.Sakaki-Yumoto, R.Derynck. TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association. Sci Signal 2012; 5:ra34; PMID:22550340; http://dx.doi.org/10.1126/scisignal.2002979
24. B.Schäfer, A.Gschwind, A.Ullrich. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 2004; 23:991-9; PMID:14647423; http://dx.doi.org/10.1038/sj.onc.1207278
25. C.Adrain, M.Zettl, Y.Christova, N.Taylor, M.Freeman. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science 2012; 335:225-8; PMID:22246777; http://dx.doi.org/10.1126/science.1214400
26. X.Li, T.Maretzky, G.Weskamp, S.Monette, X.Qing, P.D.Issuree, H.C.Crawford, D.R.McIlwain, T.W.Mak, J.E.Salmon, C.P.Blobel. iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling. Proc Natl Acad Sci U S A 2015; 112:6080-5; PMID:25918388; http://dx.doi.org/10.1073/pnas.1505649112
27. C.I.Caescu, G.R.Jeschke, B.E.Turk. Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem J 2009; 424:79-88; PMID:19715556; http://dx.doi.org/10.1042/BJ20090549
28. L.M.Parra, M.Hartmann, S.Schubach, Y.Li, P.Herrlich, A.Herrlich. Distinct intracellular domain substrate modifications selectively regulate ectodomain cleavage of NRG1 or CD44. Mol Cell Biol 2015; 35:3381-95; PMID:26217011; http://dx.doi.org/10.1128/MCB.00500-15
29. P.J.Miettinen, J.E.Berger, J.Meneses, Y.Phung, R.A.Pedersen, Z.Werb, R.Derynck. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995; 376:337-41; PMID:7630400; http://dx.doi.org/10.1038/376337a0
30. J.Scheller, A.Chalaris, C.Garbers, S.Rose-John. ADAM17:a molecular switch to control inflammation and tissue regeneration. Trends Immunol 2011; 32:380-7; PMID:21752713; http://dx.doi.org/10.1016/j.it.2011.05.005
31. D.Dreymueller, S.Uhlig, A.Ludwig. ADAM-family metalloproteinases in lung inflammation:potential therapeutic targets. Am J Physiol Lung Cell Mol Physiol 2015; 308:L325-43; PMID:25480335; http://dx.doi.org/10.1152/ajplung.00294.2014
32. S.Rose-John. ADAM17, shedding, TACE as therapeutic targets. Pharmacol Res 2013; 71:19-22; PMID:23415892; http://dx.doi.org/10.1016/j.phrs.2013.01.012
33. D.C.Blaydon, P.Biancheri, W.L.Di, V.Plagnol, R.M.Cabral, M.A.Brooke, D.A.van Heel, F.Ruschendorf, M.Toynbee, A.Walne, E.A.O'Toole, J.E.Martin, K.Lindley, T.Vulliamy, D.J.Abrams, T.T.MacDonald, J.I.Harper, D.P.Kelsell. Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med 2011; 365:1502-8; PMID:22010916; http://dx.doi.org/10.1056/NEJMoa1100721
34. R.H.Bandsma, H.van Goor, M.Yourshaw, R.K.Horlings, M.F.Jonkman, E.H.Schölvinck, A.Karrenbeld, R.Scheenstra, M.Kömhoff, P.Rump, Y.Koopman-Keemink, S.F.Nelson, J.C.Escher, E.Cutz, M.G.Martín. Loss of ADAM17 is associated with severe multiorgan dysfunction. Hum Pathol. 2015; 46:923-8; PMID:25804906; http://dx.doi.org/10.1016/j.humpath.2015.02.010
35. J.S.Fridman, E.Caulder, M.Hansbury, X.Liu, G.Yang, Q.Wang, Y.Lo, B.B.Zhou, M.Pan, S.M.Thomas, et al. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 2007; 13:1892-902; PMID:17363546; http://dx.doi.org/10.1158/1078-0432.CCR-06-2116
36. B.B.S.Zhou, M.Petyon, B.He, C.Liu, L.Girard, E.Caudler, Y.Lo, F.Baribaud, I.Mikami, N.Reguart, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER2 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006; 10:39-50; PMID:16843264; http://dx.doi.org/10.1016/j.ccr.2006.05.024
37. L.Witters, P.Scherle, S.Friedman, J.Fridman, E.Caulder, R.Newton, A.Lipton. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res 2008; 68:7083-9; PMID:18757423; http://dx.doi.org/10.1158/0008-5472.CAN-08-0739
38. B.Fingleton. Matrix metalloproteinases as valid clinical targets. Current Pharm Design 2007; 13:333-46; PMID:17313364; http://dx.doi.org/10.2174/138161207779313551
39. J.S.Fridman, P.A.Scherle, X.Liu, E.Calder, M.Hansbury, G.Yang, Q.Wang, Y.Lo, J.Zhou, W.Yao, R.C.Newton, S.Yeleswaram, S.M.Friedman, K.Vaddi. Preclinical characterization of INCB7839, a potent and selective inhibitor of ErbB ligand and HER2 receptor shedding:inhibition of ADAM10 and ADAM17 for the treatment of breast cancer. Breast Cancer Res Treat 2007; 106(Supp1):S82.
40. J.Infante, H.A.Burris, N.Lewis, R.Donehower, J.Redman, S.M.Friedman, P.A.Scherle, J.S.Fridman, J.Li, T.Emm, S.Troy, S.G.Eckhardt. A multicenter phase Ib study of the safety, pharmacokinetics, biological activity and clinical efficacy of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17. Breast Cancer Res Treat 2007; 106(Supp1):S269.
41. R.C.Newton, E.C.Bradley, R.S.Levy, D.Doval, S.Bondarde, T.P.Sahoo, D.Lokanatha, P.K.Julka, R.Nagarkar, S.M.Friedman. Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer. J Clin Oncol 2010; 28(15_suppl):(May 20 Supplement), 2010:3025.
42. Y.Zhang, M.Hegen, J.Xu, J.C.KeithJr, G.Jin, X.Du, T.Cummons, B.J.Sheppard, L.Sun, Y.Zhu, V.R.Rao, Q.Wang, W.Xu, R.Cowling, C.L.Nickerson-Nutter, J.Gibbons, J.Skotnicki, L.L.Lin, J.Levin. Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme. Int Immunopharmacol 2004; 4:1845-57; PMID:15531300; http://dx.doi.org/10.1016/j.intimp.2004.08.003
43. P.M.McGowan, M.Mullooly, F.Caiazza, S.Sukor, S.F.Madden, A.A.Maguire, A.Pierce, E.W.McDermott, J.Crown, N.O'Donovan, M.J.Duffy. ADAM-17:a novel therapeutic target for triple negative breast cancer. Ann Oncol 2013; 24:362-9; PMID:22967992; http://dx.doi.org/10.1093/annonc/mds279
44. N.B.Merchant, I.Voskresensky, C.M.Rogers, B.Lafleur, P.J.Dempsey, R.Graves-Deal, F.Revetta, A.C.Foutch, M.L.Rothenberg, M.K.Washington, R.J.Coffey. TACE/ADAM-17:a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 2008; 14:1182-91; PMID:18281553; http://dx.doi.org/10.1158/1078-0432.CCR-07-1216
45. C.J.Tape, S.H.Willems, S.L.Dombernowsky, P.L.Stanley, M.Fogarasi, W.Ouwehand, J.McCafferty, G.Murphy. Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U S A 2011; 108:5578-83; PMID:21415364; http://dx.doi.org/10.1073/pnas.1017067108
46. F.M.Richards, C.J.Tape, D.I.Jodrell, G.Murphy. Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS One 2012; 7:e40597; PMID:22792380; http://dx.doi.org/10.1371/journal.pone.0040597
47. F.Caiazza, P.M.McGowan, M.Mullooly, A.Murray, N.Synnott, N.O'Donovan, L.Flanagan, C.J.Tape, G.Murphy, J.Crown, M.J.Duffy. Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. Br J Cancer 2015; 112:1895-903; PMID:26010411; http://dx.doi.org/10.1038/bjc.2015.163
48. Y.Huang, N.Benaich, C.Tape, H.F.Kwok, G.Murphy. Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation. Int J Biol Sci 2014; 10:702-14; PMID:25013379; http://dx.doi.org/10.7150/ijbs.9326
49. J.Rios-Doria, D.Sabol, J.Chesebrough, D.Stewart, L.Xu, R.Tammali, L.Cheng, Q.Du, K.Schifferli, R.Rothstein, C.C.Leow, J.Heidbrink-Thompson, X.Jin, C.Gao, J.Friedman, B.Wilkinson, M.Damschroder, A.J.Pierce, R.E.Hollingsworth, D.A.Tice, E.F.Michelotti. A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR-mediated pathways. Mol Cancer Ther 2015; 14:1637-49; PMID:25948294; http://dx.doi.org/10.1158/1535-7163.MCT-14-1040
50. K.Yamamoto, A.Trad, A.Baumgart, L.Hüske, I.Lorenzen, A.Chalaris, J.Grötzinger, T.Dechow, J.Scheller, S.Rose-John. A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochem J 2012; 445:135-44; PMID:22509934; http://dx.doi.org/10.1042/BJ20120433
51. A.Trad, H.P.Hansen, M.Shomali, M.Peipp, K.Klausz, N.Hedemann, K.Yamamoto, A.Mauermann, C.Desel, I.Lorenzen, H.Lemke, S.Rose-John, J.Grötzinger. ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates. Cancer Immunol Immunother 2013; 62:411-21; PMID:22940887; http://dx.doi.org/10.1007/s00262-012-1346-x
52. M.J.Duffy, D.J.Lynn, A.T.Lloyd, C.M.O'Shea. The ADAMs family of proteins:from basic studies to potential clinical applications. Thromb Haemostat 2003; 89(4):622-31; PMID:12669115
53. S.M.Le Gall, P.Bobé, K.Reiss, K.Horiuchi, X.D.Niu, D.Lundell, D.R.Gibb, D.Conrad, P.Saftig, C.P.Blobel. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. Mol Biol Cell 2009; 20:1785-94; PMID:19158376; http://dx.doi.org/10.1091/mbc.E08-11-1135
54. S.Weber, M.T.Niessen, J.Prox, R.Lüllmann-Rauch, A.Schmitz, R.Schwanbeck, C.P.Blobel, E.Jorissen, B.de Strooper, C.M.Niessen, et al. The disintegrin/metalloproteinase Adam10 is essential for epidermal integrity and Notch-mediated signaling. Development 2011; 138:495-505; PMID:21205794; http://dx.doi.org/10.1242/dev.055210
55. E.C.Bozhulak, G.Weinmaster. Selective use of ADAM10 and ADAM17 in activation of Notch 1 signaling. Mol Cell Biol 2009; 29:5679-95; PMID:19704010; http://dx.doi.org/10.1128/MCB.00406-09
56. P.H.Kuhn, H.Wang, B.Dislich, A.Colombo, U.Zeitschel, J.W.Ellwart, E.Kremmer, S.Rossner, S.F.Lichtenthaler. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 2010; 29:3020-32; PMID:20676056; http://dx.doi.org/10.1038/emboj.2010.167
57. V.Vingtdeux, P.Marambaud. Identification and biology of α-secretase. J Neurochem 2012; 120(Suppl 1):34-45; PMID:22121879; http://dx.doi.org/10.1111/j.1471-4159.2011.07477.x
58. U.Sahin, G.Weskamp, K.Kelly, H.M.Zhou, S.Higashiyama, J.Peschon, D.Hartmann, P.Saftig, C.P.Blobel. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164:769-79; PMID:14993236; http://dx.doi.org/10.1083/jcb.200307137
59. U.Sahin, C.P.Blobel Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. FEBS Lett 2007; 581:41-44; PMID:17169360; http://dx.doi.org/10.1016/j.febslet.2006.11.074
60. I.Espinoza, L.Miele. Deadly crosstalk:Notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett 2013; 341:41-5; PMID:23973264; http://dx.doi.org/10.1016/j.canlet.2013.08.027
61. X.Yuan, H.Wu, H.Xu, H.Xiong, Q.Chu, S.Yu, G.S.Wu, K.Wu. Notch signaling:An emerging therapeutic target for cancer treatment. Cancer Lett 2015; 369:20-7; PMID:26341688; http://dx.doi.org/10.1016/j.canlet.2015.07.048
62. E.C.Bozhulak, G.Weinmaster. Selective use of ADAM10 and ADAM17 in activation of Notch 1 signaling. Mol Cell Biol 2009; 29:5679-95; PMID:19704010; http://dx.doi.org/10.1128/MCB.00406-09
63. T.Maretzky, K.Reiss, A.Ludwig, J.Buchholz, F.Scholz, E.Proksch, B.de Strooper, D.Hartmann, P.Saftig. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and β-catenin translocation. Proc Natl Acad Sci USA 2005; 102:9182-87; PMID:15958533; http://dx.doi.org/10.1073/pnas.0500918102
64. K.Reiss, T.Maretzky, A.Ludwig, T.Tousseyn, B.de Strooper, D.Hartmann, P.Saftig. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J 2005; 24:742-52. Erratum in:EMBO J. 2005; 24:1762; PMID:15692570; http://dx.doi.org/10.1038/sj.emboj.7600548
65. T.Maretzky, M.Schulte, A.Ludwig, S.Rose-John, C.Blobel, D.Hartmann, P.Altevogt, P.Saftig, K.Reiss. L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol 2005; 25:9040-53; PMID:16199880; http://dx.doi.org/10.1128/MCB.25.20.9040-9053.2005
66. S.Mechtersheimer, P.Gutwein, N.Agmon-Levin, A.Stoeck, M.Oleszewski, S.Riedle, R.Postina, F.Fahrenholz, M.Fogel, V.Lemmon, et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 2001; 155:661-73.Erratum in:J Cell Biol 2001; 155:1359; PMID:11706054; http://dx.doi.org/10.1083/jcb.200101099
67. T.Murai, T.Miyauchi, T.Yanagida, Y.Sako. Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10. Biochem J 2006; 395:65-71; PMID:16390331; http://dx.doi.org/10.1042/BJ20050582
68. D.Hartmann, B.de Strooper, L.Serneels, K.Craessaerts, A.Herreman, W.Annaert, L.Umans, T.Lübke, A.Lena Illert, K.von Figura, P.Saftig. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet. 2002; 11:2615-24; PMID:12354787; http://dx.doi.org/10.1093/hmg/11.21.2615
69. D.R.Gibb, S.J.Saleem, N.S.Chaimowitz, J.Mathews, D.H.Conrad. The emergence of ADAM10 as a regulator of lymphocyte development and autoimmunity. Mol Immunol 2011; 48:1319-27; PMID:21236490; http://dx.doi.org/10.1016/j.molimm.2010.12.005
70. M.Kim, J.Suh, D.Romano, M.H.Truong, K.Mullin, B.Hooli, D.Norton, G.Tesco, K.Elliott, S.L.Wagner, R.D.Moir, K.D.Becker, R.E.Tanzi. Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum Mol Genet 2009; 18:3987-96; PMID:19608551; http://dx.doi.org/10.1093/hmg/ddp323
71. M.Mullooly, P.M.McGowan, S.A.Kennedy, S.F.Madden, J.Crown, N.O' Donovan, M.J.Duffy. ADAM10:a new player in breast cancer progression? Br J Cancer 2015; 113:945-51; PMID:26284334; http://dx.doi.org/10.1038/bjc.2015.288
72. M.M.Gaida, N.Haag, F.Gunther, D.F.Tschaharganeh, P.Schirmacher, H.Friess, N.A.Giese, J.Schmidt, M.N.Wente. Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int J Mol Med 2010 Aug; 26(2):281-8; PMID:20596609
73. S.B.Lee, A.Schramme, K.Doberstein, R.Drummer, M.S.Abdel-Bakky, S.Keller, P.Altevogt, S.T.Oh, J.Reichrath, D.Oxmann, et al. ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J Invest Dermatol 2010; 130:763-73; PMID:19865098; http://dx.doi.org/10.1038/jid.2009.335
74. L.Fu, N.Liu, Y.Han, C.Xie, Q.Li, E.Wang. ADAM10 regulates proliferation, invasion, and chemoresistance of bladder cancer cells. Tumour Biol 2014; 35:9263-8; PMID:24935471; http://dx.doi.org/10.1007/s13277-014-2201-9
75. M.L.Moss, A.Stoeck, W.Yan, P.J.Dempsey. ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol 2008; 9:2-8; PMID:18289051; http://dx.doi.org/10.2174/138920108783497613
76. A.Ludwig, C.Hundhausen, M.H.Lambert, N.Broadway, R.C.Andrews, D.M.Bickett, M.A.Leesnitzer, J.D.Becherer. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 2005; 8:161-71; PMID:15777180; http://dx.doi.org/10.2174/1386207053258488
77. C.Hundhausen, D.Misztela, T.A.Berkhout, N.Broadway, P.Saftig, K.Reiss, D.Hartmann, F.Fahrenholz, R.Postina, V.Matthews, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003; 102:1186-95; PMID:12714508; http://dx.doi.org/10.1182/blood-2002-12-3775
78. S.Ma, J.Xu, X.Wang, Q.Y.Wu, J.Cao, Z.Y.Li, L.Y.Zeng, C.Chen, K.L.Xu. Effect of ADAM10 Inhibitor GI254023X on proliferation and apoptosis of acute T-lymphoblastic leukemia Jurkat cells in vitro and its possible mechanisms. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2015 Aug; 23(4):950-5; PMID:26314424; http://dx.doi.org/10.7534/j.issn.1009-2137.2015.04.008
79. M.F.Rimawi, R.Schiff, C.K.Osborne. Targeting HER2 for the treatment of breast cancer. Annu Rev Med 2015; 66:111-28; PMID:25587647; http://dx.doi.org/10.1146/annurev-med-042513-015127
80. K.Feldinger, D.Generali, G.Kramer-Marek, M.Gijsen, T.B.Ng, J.H.Wong, C.Strina, M.Cappelletti, D.Andreis, J.L.Li, et al. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget 2014; 5:6633-46; PMID:24952873; http://dx.doi.org/10.18632/oncotarget.1955
81. M.J.Duffy, J.Crown, M.Mullooly. ADAM10 and ADAM17:new players in trastuzumab resistance. Oncotarget 2014; 5:10963-4; PMID:25460503; http://dx.doi.org/10.18632/oncotarget.2794
82. H.Rao, G.Lu, H.Kajiya, V.Garcia-Palacios, N.Kurihara, J.Anderson, K.Patrene, D.Sheppard, H.C.Blair, J.J.Windle, S.J.Choi, G.D.Roodman. Alpha9beta1:a novel osteoclast integrin that regulates osteoclast formation and function. J Bone Miner Res 2006; 21:1657-65; PMID:16995821; http://dx.doi.org/10.1359/jbmr.060718
83. S.Srinivasan, M.Romagnoli, A.Bohm, G.E.Sonenshein. N-glycosylation regulates ADAM8 processing and activation. J Biol Chem 2014; 289:33676-88; PMID:25336660; http://dx.doi.org/10.1074/jbc.M114.594242
84. T.Hall, J.W.Leone, J.F.Wiese, D.W.Griggs, L.E.Pegg, A.M.Pauley, A.G.Tomasselli, M.D.Zack. Autoactivation of human ADAM8:a novel pre-processing step is required for catalytic activity. Biosci Rep 2009; 29:217-28; PMID:18811590; http://dx.doi.org/10.1042/BSR20080145
85. G.Weskamp, J.W.Ford, J.Sturgill, S.Martin, A.J.Docherty, S.Swendeman, N.Broadway, D.Hartmann, P.Saftig, S.Umland, A.Sehara-Fujisawa, R.A.Black, A.Ludwig, J.D.Becherer, D.H.Conrad, C.P.Blobel. ADAM10 is a principal ‘sheddase’ of the low-affinity immunoglobulin E receptor CD23. Nat Immunol 2006; 7:1293-8; PMID:17072319; http://dx.doi.org/10.1038/ni1399
86. J.W.Bartsch, D.Wildeboer, G.Koller, S.Naus, A.Rittger, M.L.Moss, Y.Minai, H.Jockusch. Tumor necrosis factor-alpha (TNF-alpha) regulates shedding of TNF-alpha receptor 1 by the metalloprotease-disintegrin ADAM8:evidence for a protease-regulated feedback loop in neuroprotection. J Neurosci 2010; 30:12210-8; PMID:20826683; http://dx.doi.org/10.1523/JNEUROSCI.1520-10.2010
87. M.Gómez-Gaviro, M.Domínguez-Luis, J.Canchado, J.Calafat, H.Janssen, E.Lara-Pezzi, A.Fourie, A.Tugores, A.Valenzuela-Fernández, F.Mollinedo, F.Sánchez-Madrid, F.Díaz-González. Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding. J Immunol 2007; 178:8053-63; PMID:17548643; http://dx.doi.org/10.4049/jimmunol.178.12.8053
88. K.Kelly, G.Hutchinson, D.Nebenius-Oosthuizen, A.J.Smith, J.W.Bartsch, K.Horiuchi, A.Rittger, K.Manova, A.J.Docherty, C.P.Blobel. Metalloprotease-disintegrin ADAM8:expression analysis and targeted deletion in mice. Dev Dyn 2005; 232:221-31; PMID:15580619; http://dx.doi.org/10.1002/dvdy.20221
89. M.Romagnoli, N.D.Mineva, M.Polmear, C.Conrad, S.Srinivasan, D.Loussouarn, S.Barillé-Nion, I.Georgakoudi, Á.Dagg, E.W.McDermott, M.J.Duffy, P.M.McGowan, U.Schlomann, M.Parsons, J.W.Bartsch, G.E.Sonenshein. ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol Med 2014 Feb; 6(2):278-94; PMID:24375628; http://dx.doi.org/10.1002/emmm.201303373
90. U.Schlomann, G.Koller, C.Conrad, T.Ferdous, P.Golfi, A.M.Garcia, S.Höfling, M.Parsons, P.Costa, R.Soper, M.Bossard, T.Hagemann, R.Roshani, N.Sewald, R.R.Ketchem, M.L.Moss, F.H.Rasmussen, M.A.Miller, D.A.Lauffenburger, D.A.Tuveson, C.Nimsky, J.W.Bartsch. ADAM8 as a drug target in pancreatic cancer. Nat Commun 2015; 6:6175; PMID:25629724; http://dx.doi.org/10.1038/ncomms7175
91. S.Mochizuki, Y.Okada. ADAM28 as a target for human cancers. Curr Pharm Des 2009; 15:2349-58; PMID:19601836; http://dx.doi.org/10.2174/138161209788682424
92. L.Howard, R.A.Maciewicz, C.P.Blobel. Cloning and characterization of ADAM28:evidence for autocatalytic pro-domain removal and for cell surface localization of mature ADAM28. Biochem J 2000; 348:21-27; PMID:10794709; http://dx.doi.org/10.1042/bj3480021
93. S.Mochizuki, K.Soejima, M.Shimoda, H.Abe, A.Sasaki, H.J.Okano, H.Okano, Y.Okada. Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst 2012; 104:906-22; PMID:22636800; http://dx.doi.org/10.1093/jnci/djs232
94. A.M.Fourie, F.Coles, V.Moreno, L.Karlsson. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J Biol Chem 2003; 278:30469-77; PMID:12777399; http://dx.doi.org/10.1074/jbc.M213157200
95. Y.Mitsui, S.Mochizuki, T.Kodama, M.Shimoda, T.Ohtsuka, T.Shiomi, M.Chijiiwa, T.Ikeda, M.Kitajima, Y.Okada. ADAM28 is overexpressed in human breast carcinomas:implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res 2006; 66:9913-20; PMID:17047053; http://dx.doi.org/10.1158/0008-5472.CAN-06-0377
96. L.C.Bridges, D.Sheppard, R.D.Bowditch. ADAM disintegrin-like domain recognition by the lymphocyte integrins alpha4beta1 and alpha4beta7. Biochem J 2005; 387:101-8; PMID:15504110; http://dx.doi.org/10.1042/BJ20041444
97. J.M.Kim, H.C.Jeung, S.Y.Rha, E.J.Yu, T.S.Kim, Y.K.Shin, X.Zhang, K.H.Park, S.W.Park, H.C.Chung, G.Powis. The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. Mol Cancer Ther 2014; 13:3074-85; PMID:25344581; http://dx.doi.org/10.1158/1535-7163.MCT-13-1001
98. C.Y.Lin, H.J.Chen, C.C.Huang, L.C.Lai, T.P.Lu, G.C.Tseng, T.T.Kuo, Q.Y.Kuok, J.L.Hsu, S.Y.Sung, M.C.Hung, Y.P.Sher. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Res 2014; 74:5229-43; PMID:25060522; http://dx.doi.org/10.1158/0008-5472.CAN-13-2995
99. R.Albrechtsen, M.Kveiborg, D.Stautz, J.Vikeså, J.B.Noer, A.Kotzsh, F.C.Nielsen, U.M.Wewer, C.Fröhlich. ADAM12 redistributes and activates MMP-14, resulting in gelatin degradation, reduced apoptosis and increased tumor growth. J Cell Sci 2013; 126:4707-20; PMID:24006261; http://dx.doi.org/10.1242/jcs.129510
100. H.Li, S.Duhachek-Muggy, S.Dubnicka, A.Zolkiewska. Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype. Breast Cancer Res Treat 2013; 139:691-703; PMID:23771733; http://dx.doi.org/10.1007/s10549-013-2602-2
101. D.D.Dong, H.Zhou, G.Li. ADAM15 targets MMP9 activity to promote lung cancer cell invasion. Oncol Rep 2015 Nov; 34(5):2451-60; PMID:26323669; http://dx.doi.org/10.3892/or.2015.4203
102. C.Toquet, A.Colson, A.Jarry, S.Bezieau, C.Volteau, P.Boisseau, D.Merlin, C.L.Laboisse, J.F.Mosnier. ADAM15 to α5β1 integrin switch in colon carcinoma cells:a late event in cancer progression associated with tumor dedifferentiation and poor prognosis. Int J Cancer 2012; 130:278-87; PMID:21190186; http://dx.doi.org/10.1002/ijc.25891
103. D.McCartan, J.C.Bolger, A.Fagan, C.Byrne, Y.Hao, L.Qin, M.McIlroy, J.Xu, A.D.Hill, P.Ó.Gaora, L.S.Young. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. Cancer Res 2012; 72:220-9; PMID:22072566; http://dx.doi.org/10.1158/0008-5472.CAN-11-1976
104. J.C.Bolger, L.S.Young. ADAM22 as a prognostic and therapeutic drug target in the treatment of endocrine-resistant breast cancer. Vitam Horm 2013; 93:307-21; PMID:23810013; http://dx.doi.org/10.1016/B978-0-12-416673-8.00014-9